Suppr超能文献

遗传性出血性毛细血管扩张症患者肺和脑动静脉畸形的血管内治疗

Endovascular treatment of pulmonary and cerebral arteriovenous malformations in patients affected by hereditary haemorrhagic teleangiectasia.

作者信息

De Cillis E, Burdi N, Bortone A S, D'Agostino D, Fiore T, Ettorre G C, Resta M

机构信息

Institute of Cardiac Surgery, University of Bari, Bari, Italy.

出版信息

Curr Pharm Des. 2006;12(10):1243-8. doi: 10.2174/138161206776361237.

Abstract

Hereditary Haemorrhagic Teleangiectasia (HHT) is a vascular disorder of angiogenesis transmitted in an autosomal dominant pattern, characterised by heterogeneity in clinical manifestations. One of the most important organ involved is lung, including pulmonary arteriovenous malformations (PAVM). PAVM occur in 20 to 30% of the HHT population and recently are considered a marker of disease. PAVM are direct artery-to-vein connections with low pressure and without an interveining capillary bed. PAVM are classified as simple (supplied by one feeding artery) or complex (receiving blood supply from two or more feeding artery). According to the international reports, treatment it's recommendable for all PAVM with feeding vessels 3mm or larger, in order to reduce the risk of cerebral ischaemia and neurologic manifestations frequently attributed to paradoxical embolisation. Transcatheter embolotherapy of PAVM is a form of treatment based on occlusion of the feeding artery to a PAVM by using platinum coils or detachable balloons. The technique of coil embolisation involves the exact localisation of PAVM by pulmonary angiography followed by superselective percutaneous caheterisation of feeding artery obtained by using a dedicated 7F guiding catheter, which coaxially allocates a 5F hydrophilic catheter advanced in order to perform both superselective angiography of feeding artery and embolisation itself. Inside the 5F catheter the platinum coils are advanced using a .035'' guide-wire and released until an optimal occlusion of feeding artery is achieved. At the end of the procedure angiographic control is performed in order to verify the occlusion of feeding artery. The use of platinum coils is preferable over detachable balloons when feeding artery are greater than 7 mm in diameter and have irregular anatomical configuration. On the other hand, the principal advantage of using detachable balloons is that the balloon itself can be deflated and repositioned if necessary. Transcatheter embolotherapy is technically safe and clinically effective and may represent the primary choice of treatment in HHT patients. On the other hand the most common complications of this treatment (pleurisy and air embolism) can be prevented by using some tips during the embolisation procedure like "anchor technique," "scaffold technique" and "balloon assisted technique." Cerebral arteriovenous malformations (CAVM) are present in 10-20% of patients with HHT and multiple in 50% of cases. Cortical surface is the most frequent localisation. Angiography is needed to diagnose all CAVM and to clarify the angioarchitecture of the lesion. In HHT CAVM are usually either micro-AVM, with a nidus not bigger than 1 cm, or small AVM, with a nidus between 1 and 3 cm. Quite frequently there are lesions characterised by arteriovenous fistulas. In the three patterns of CAVM usually found in HHT, small AVM are the most risky for bleeding although the risk is lower than that associated with sporadic ones. It is estimated from 0.38 to 0.69% per year in spite of the general incidence of bleeding in sporadic CAVM that ranges from 2 to 4% per year. In HHT patients, at present, the precise indications and timing of treatment are not established. Trend is to treat small AVM and AVF and to follow-up micro-AVM with MRI and angiography. As for sporadic CAVM, treatment of small AVM is usually referred to stereotactic radiosurgery. Endovascular embolisation is proposable if the lesion is easily reachable by microcatheterism and the position of the microcatheter is safe. Glue is used for embolisation and the technique is briefly discussed.

摘要

遗传性出血性毛细血管扩张症(HHT)是一种以常染色体显性模式遗传的血管生成障碍性疾病,其临床表现具有异质性。肺部是受影响最重要的器官之一,包括肺动静脉畸形(PAVM)。PAVM在20%至30%的HHT患者中出现,最近被视为疾病的一个标志。PAVM是动脉与静脉之间的直接连接,压力低且没有中间毛细血管床。PAVM分为简单型(由一根供血动脉供血)或复杂型(接受两根或更多供血动脉的血液供应)。根据国际报告,对于所有供血血管直径为3毫米或更大的PAVM,建议进行治疗,以降低常因反常栓塞导致的脑缺血和神经症状的风险。PAVM的经导管栓塞治疗是一种基于使用铂线圈或可脱性球囊闭塞PAVM供血动脉的治疗方法。线圈栓塞技术包括通过肺血管造影精确确定PAVM的位置,然后使用专用的7F引导导管经皮超选择性插管至供血动脉,该引导导管同轴置入一根5F亲水导管,以进行供血动脉的超选择性血管造影和栓塞操作本身。在5F导管内,使用0.035英寸导丝推进铂线圈并释放,直至实现供血动脉的最佳闭塞。手术结束时进行血管造影控制,以验证供血动脉的闭塞情况。当供血动脉直径大于7毫米且解剖结构不规则时,使用铂线圈优于可脱性球囊。另一方面,使用可脱性球囊的主要优点是如有必要,球囊本身可放气并重新定位。经导管栓塞治疗在技术上是安全的,临床效果良好,可能是HHT患者的主要治疗选择。另一方面,这种治疗最常见的并发症(胸膜炎和气栓)可通过在栓塞过程中使用一些技巧来预防,如“锚定技术”“支架技术”和“球囊辅助技术”。脑动静脉畸形(CAVM)在10%至20%的HHT患者中存在,其中50%为多发。皮质表面是最常见的部位。需要进行血管造影以诊断所有CAVM并明确病变的血管结构。在HHT中,CAVM通常要么是微AVM,其病灶不大于1厘米,要么是小AVM,其病灶在1至3厘米之间。相当常见的是存在以动静脉瘘为特征的病变。在HHT中通常发现的三种CAVM类型中,小AVM出血风险最高,尽管其风险低于散发性CAVM。据估计,每年发生率为0.38%至0.69%,而散发性CAVM的总体出血发生率为每年2%至4%。目前,在HHT患者中,治疗的精确指征和时机尚未确定。趋势是治疗小AVM和AVF,并通过MRI和血管造影对微AVM进行随访。对于散发性CAVM,小AVM的治疗通常采用立体定向放射外科。如果病变可通过微导管轻松到达且微导管位置安全,则可考虑进行血管内栓塞。使用胶水进行栓塞,并简要讨论了该技术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验